Mylan Pharmaceuticals Settles for $73.5 Million in EpiPen Antitrust Case with Pfizer

Pieter Gunst01 mins

Mylan Pharmaceuticals will pay $73.5 million to address accusations of collusion with Pfizer to artificially increase the cost of EpiPen, an emergency allergy treatment. This settlement forms part of ongoing legal proceedings in a Kansas federal court, involving a class of direct purchasers. Consequently, the total amount Mylan has agreed to settle for has reached $123.5 million. More information on this case is available through Law360.